These findings underscore the pivotal role of the aberrantly activated UPR, governed by the NFKB-miR-29b/c axis, in driving disease progression in bladder cancer and highlight that restoring miR-29b/c expression offers a promising strategy to limit UPR and mitigate tumor aggressiveness in bladder cancer patients. This evidence concerns the gene NFKB1 and urinary bladder cancer.